Apolipoproteins E

• 

  Subject Areas on Research

  • 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner. 
  • A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression. 
  • A blood-based signature of cerebrospinal fluid Aβ1-42 status. 
  • A deficit in astroglial organization causes the impaired reactive sprouting in human apolipoprotein E4 targeted replacement mice. 
  • A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing. 
  • A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. 
  • A metabolomic signature of the APOE2 allele. 
  • A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. 
  • A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. 
  • A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. 
  • A population study of Alzheimer's disease: findings from the Cache County Study on Memory, Health, and Aging. 
  • A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. 
  • A role of matrix metalloproteinase-8 in atherosclerosis. 
  • A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. 
  • APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice. 
  • APOE Isoforms Control Pathogenic Subretinal Inflammation in Age-Related Macular Degeneration. 
  • APOE and AD concordance in twin pairs as predictors of AD in first-degree relatives. 
  • APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. 
  • APOE epsilon4 and low cholesterol as risks for depression in a biracial elderly community sample. 
  • APOE epsilon4 as a predictor of subjective quality of life in a biracial older person community sample. 
  • APOE genotype affects outcome in a murine model of sepsis: implications for a new treatment strategy. 
  • APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. 
  • APOE genotype and hippocampal volume change in geriatric depression. 
  • APOE genotype is a risk factor for neuropathy severity in diabetic patients. 
  • APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. 
  • APOE genotype regulates pathology and disease progression in synucleinopathy. 
  • APOE genotype-specific differences in human and mouse macrophage nitric oxide production. 
  • APOE genotype-specific differences in the innate immune response. 
  • APOE polymorphism is associated with risk of severe sepsis in surgical patients. 
  • APOE region molecular signatures of Alzheimer's disease across races/ethnicities. 
  • APOE ɛ4 allele and TOMM40-APOC1 variants jointly contribute to survival to older ages. 
  • APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. 
  • APOE ε4 Modifies Effect of Residential Greenness on Cognitive Function among Older Adults: A Longitudinal Analysis in China. 
  • APOE, TOMM40, and sex interactions on neural network connectivity. 
  • APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. 
  • APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics. 
  • APOE/TOMM40 genetic loci, white matter hyperintensities, and cerebral microbleeds. 
  • APOE2 allele increased in tardive dyskinesia. 
  • APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2. 
  • APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's. 
  • ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. 
  • Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. 
  • Accuracy of Inferred APOE Genotypes for a Range of Genotyping Arrays and Imputation Reference Panels. 
  • Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. 
  • African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles. 
  • Age at onset in two common neurodegenerative diseases is genetically controlled. 
  • Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. 
  • Altered immune responses in apolipoprotein E-deficient mice. 
  • Alzheimer's Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. 
  • Alzheimer's disease and apolipoprotein E-4 allele in an Amish population. 
  • Alzheimer's disease and possible gene interaction. 
  • Alzheimer's disease in the National Academy of Sciences-National Research Council Registry of Aging Twin Veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. 
  • Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. 
  • Alzheimer's disease susceptibility genes APOE and TOMM40, and hippocampal volumes in the Lothian birth cohort 1936. 
  • Alzheimer's disease. Risky apolipoprotein in brain. 
  • An apoE-derived mimic peptide, COG1410, alleviates early brain injury via reducing apoptosis and neuroinflammation in a mouse model of subarachnoid hemorrhage. 
  • An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. 
  • An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. 
  • An autosomal genomic screen for dementia in an extended Amish family. 
  • Analysis of European mitochondrial haplogroups with Alzheimer disease risk. 
  • Analysis of association at single nucleotide polymorphisms in the APOE region. 
  • Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). 
  • Analysis of pleiotropic genetic effects on cognitive impairment, systemic inflammation, and plasma lipids in the Health and Retirement Study. 
  • Androgen-mediated immune function is altered by the apolipoprotein E gene. 
  • Angiopoietin-1 promotes atherosclerosis by increasing the proportion of circulating Gr1+ monocytes. 
  • Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide. 
  • Angiotensin II mobilizes spleen monocytes to promote the development of abdominal aortic aneurysm in Apoe-/- mice. 
  • Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. 
  • Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. 
  • Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. 
  • Apo E structure determines VLDL clearance and atherosclerosis risk in mice. 
  • ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice. 
  • ApoE genotype and survival from intracerebral haemorrhage. 
  • ApoE genotype-specific inhibition of apoptosis. 
  • ApoE isoform affects LTP in human targeted replacement mice. 
  • ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. 
  • ApoE mimetic ameliorates motor deficit and tissue damage in rat spinal cord injury. 
  • ApoE mimetic improves pathology and memory in a model of Alzheimer's disease. 
  • ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. 
  • ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer's disease. 
  • Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. 
  • Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. 
  • Apolipoprotein E E4 allele and risk of dementia. 
  • Apolipoprotein E Exerts a Whole-Brain Protective Property by Promoting M1? Microglia Quiescence After Experimental Subarachnoid Hemorrhage in Mice. 
  • Apolipoprotein E Mimetic Peptide Increases Cerebral Glucose Uptake by Reducing Blood-Brain Barrier Disruption after Controlled Cortical Impact in Mice: An 18F-Fluorodeoxyglucose PET/CT Study. 
  • Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study. 
  • Apolipoprotein E acts to increase nitric oxide production in macrophages by stimulating arginine transport. 
  • Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. 
  • Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. 
  • Apolipoprotein E alleles and sensorineural hearing loss. 
  • Apolipoprotein E and Alzheimer disease. 
  • Apolipoprotein E and Alzheimer's disease. 
  • Apolipoprotein E and Alzheimer's disease. 
  • Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms. 
  • Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade. 
  • Apolipoprotein E and brain injury: implications for children. 
  • Apolipoprotein E and cognitive decline in Alzheimer's disease. 
  • Apolipoprotein E and mimetic peptide initiate a calcium-dependent signaling response in macrophages. 
  • Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. 
  • Apolipoprotein E and neuromuscular disease: a critical review of the literature. 
  • Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. 
  • Apolipoprotein E and the CNS response to injury. 
  • Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. 
  • Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor. 
  • Apolipoprotein E controls the risk and age at onset of Parkinson disease. 
  • Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. 
  • Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with normal cognition. 
  • Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. 
  • Apolipoprotein E epsilon 4. 
  • Apolipoprotein E epsilon2 does not increase risk of early-onset sporadic Alzheimer's disease. 
  • Apolipoprotein E epsilon4 and risk of mortality in African American and white older community residents. 
  • Apolipoprotein E expression and behavioral toxicity of high charge, high energy (HZE) particle radiation. 
  • Apolipoprotein E gene and retinal microvascular signs in older people: the Cardiovascular Health Study. 
  • Apolipoprotein E gene polymorphisms are not associated with diabetic retinopathy: the atherosclerosis risk in communities study. 
  • Apolipoprotein E genotype and S100beta after cardiac surgery: is inflammation the link? 
  • Apolipoprotein E genotype and major depression in a community of older adults. The Cache County Study. 
  • Apolipoprotein E genotype and mortality: findings from the Cache County Study. 
  • Apolipoprotein E genotype and outcome in infants with hypoxic-ischemic encephalopathy. 
  • Apolipoprotein E genotype and subcortical vascular lesions in older depressed patients and control subjects. 
  • Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. 
  • Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass. 
  • Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. 
  • Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. 
  • Apolipoprotein E in Creutzfeldt-Jacob disease. 
  • Apolipoprotein E in Creutzfeldt-Jakob disease. 
  • Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. 
  • Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. 
  • Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. 
  • Apolipoprotein E isoform mediated regulation of nitric oxide release. 
  • Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. 
  • Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. 
  • Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. 
  • Apolipoprotein E modifies neurological outcome by affecting cerebral edema but not hematoma size after intracerebral hemorrhage in humans. 
  • Apolipoprotein E modifies the CNS response to injury via a histamine-mediated pathway. 
  • Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. 
  • Apolipoprotein E plays a key role against cryptosporidial infection in transgenic undernourished mice. 
  • Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. 
  • Apolipoprotein E polymorphism and the risk of acute nephropathy after cardiac surgery. 
  • Apolipoprotein E polymorphism, life stress and self-reported health among older adults. 
  • Apolipoprotein E polymorphisms and age at first coronary artery bypass graft. 
  • Apolipoprotein E protects against NMDA excitotoxicity. 
  • Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity. 
  • Apolipoprotein E region molecular signatures of Alzheimer's disease. 
  • Apolipoprotein E suppresses glial cell secretion of TNF alpha. 
  • Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. 
  • Apolipoprotein E-Mimetic COG1410 Reduces Acute Vasogenic Edema following Traumatic Brain Injury. 
  • Apolipoprotein E-deficient mice created by systemic administration of antisense oligodeoxynucleotides: a new model for lipoprotein metabolism studies. 
  • Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. 
  • Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. 
  • Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease. 
  • Apolipoprotein E-epsilon 4 frequency in geriatric depression. 
  • Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner. 
  • Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease. 
  • Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma. 
  • Apolipoprotein E4 increases aortic atheroma burden in cardiac surgical patients. 
  • Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. 
  • Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. 
  • Apolipoprotein Eɛ2 Is Associated with New Hemorrhage Risk in Brain Arteriovenous Malformations. 
  • Apolipoprotein-E allele-specific regulation of nitric oxide production. 
  • ApolipoproteinE mimetic peptides improve outcome after focal ischemia. 
  • Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. 
  • Are APOE ɛ genotype and TOMM40 poly-T repeat length associations with cognitive ageing mediated by brain white matter tract integrity? 
  • Are C-reactive protein associated genetic variants associated with serum levels and retinal markers of microvascular pathology in Asian populations from Singapore? 
  • Arsenic Exposure, Blood DNA Methylation, and Cardiovascular Disease. 
  • Association between bleomycin hydrolase and Alzheimer's disease in caucasians. 
  • Association of ALS with head injury, cigarette smoking and APOE genotypes. 
  • Association of APOE ε4 genotype and lifestyle with cognitive function among Chinese adults aged 80 years and older: A cross-sectional study. 
  • Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity: A Meta-analysis. 
  • Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. 
  • Association of genetic polymorphisms with risk of renal injury after coronary bypass graft surgery. 
  • Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. 
  • Association of the apolipoprotein E gene with age-related macular degeneration: possible effect modification by family history, age, and gender. 
  • Associations between APOE variants and metabolic traits and the impact of psychological stress. 
  • Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease biomarkers. 
  • Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E. 
  • B cell depletion reduces the development of atherosclerosis in mice. 
  • Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County Study. 
  • Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. 
  • Blockade of nicotinic acetylcholine receptors suppresses hippocampal long-term potentiation in wild-type but not ApoE4 targeted replacement mice. 
  • Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration. 
  • Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. 
  • COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain. 
  • COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. 
  • COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia. 
  • COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat. 
  • CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. 
  • Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4. 
  • Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. 
  • Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. 
  • Cerebrospinal fluid cortisol concentrations in healthy elderly are affected by both APOE and TOMM40 variants. 
  • Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. 
  • Characterization and identification of measurable endpoints in a mouse model featuring age-related retinal pathologies: a platform to test therapies. 
  • Characterization of the poly-T variant in the TOMM40 gene in diverse populations. 
  • Cis-acting human ApoE tissue expression element is associated with human pattern of intraneuronal ApoE in transgenic mice. 
  • Clinical application of apolipoprotein E genotyping to Alzheimer's disease. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Complement-Mediated Regulation of Apolipoprotein E in Cultured Human RPE Cells. 
  • Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. 
  • Complex genetic disease: can genetic strategies in Alzheimer's disease and new genetic mechanisms be applied to epilepsy? 
  • Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease. 
  • Congenital absence of apolipoprotein E and neurological function. 
  • Corpora amylacea are associated with tau burden and cognitive status in Alzheimer's disease. 
  • Crosslinking of apolipoprotein E by products of lipid peroxidation. 
  • D2 dopamine receptor A1 allele in Alzheimer disease and aging. 
  • Definitive roles of TOMM40-APOE-APOC1 variants in the Alzheimer's risk. 
  • Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. 
  • Dementia with Lewy bodies and Alzheimer's disease. 
  • Dementia, asymmetry of temporal lobe structures, and apolipoprotein E genotype: relationships to cerebral atrophy and neuropsychological impairment. 
  • Dietary patterns and the metabolic syndrome in obese and non-obese Framingham women. 
  • Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. 
  • Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins. 
  • Discovery of biomarker candidates for coronary artery disease from an APOE-knock out mouse model using iTRAQ-based multiplex quantitative proteomics. 
  • Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. 
  • Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. 
  • Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. 
  • Dual-energy computed tomography imaging of atherosclerotic plaques in a mouse model using a liposomal-iodine nanoparticle contrast agent. 
  • Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. 
  • Early parental death and remarriage of widowed parents as risk factors for Alzheimer disease: the Cache County study. 
  • Effect of APOE and CD33 on Cognitive Decline. 
  • Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. 
  • Effect of apolipoprotein E genotype on cerebral autoregulation during cardiopulmonary bypass. 
  • Effect of apolipoprotein E genotype on in-hospital mortality following intracerebral haemorrhage. 
  • Effect of apolipoproteins on the induction of hepatic steatosis in rats. 
  • Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. 
  • Effects of sex and genotype in human APOE-targeted replacement mice on alcohol self-administration measured with the automated IntelliCage system before and after repeated mild traumatic brain injury. 
  • Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production. 
  • Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. 
  • Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. 
  • Evaluation of genotype-specific survival using joint analysis of genetic and non-genetic subsamples of longitudinal data. 
  • Expression of the apolipoprotein E gene does not affect motor recovery after sensorimotor cortex injury in the mouse. 
  • Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. 
  • Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts. 
  • Fast Algorithms for Conducting Large-Scale GWAS of Age-at-Onset Traits Using Cox Mixed-Effects Models. 
  • Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. 
  • Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. 
  • Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis 
  • Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. 
  • Fuzzy set analyses of genetic determinants of health and disability status. 
  • G protein-coupled receptor kinase-5 attenuates atherosclerosis by regulating receptor tyrosine kinases and 7-transmembrane receptors. 
  • GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. 
  • Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. 
  • Genetic considerations relevant to intracranial hemorrhage and brain arteriovenous malformations. 
  • Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. 
  • Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. 
  • Genetic susceptibility to Alzheimer disease. 
  • Genetic variation at a single locus and age of onset for Alzheimer's disease. 
  • Genetics of Alzheimer's disease. 
  • Genetics of Human Longevity From Incomplete Data: New Findings From the Long Life Family Study. 
  • Genome-wide analysis identified abundant genetic modulators of contributions of the apolipoprotein E alleles to Alzheimer's disease risk. 
  • Hippocampal infusions of apolipoprotein E peptides induce long-lasting cognitive impairment. 
  • Hippocampal sulcal cavities on MRI: relationship to age and apolipoprotein E genotype. 
  • Hippocampal volume and incident dementia in geriatric depression. 
  • Home surveillance program prevents interstage mortality after the Norwood procedure. 
  • Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. 
  • Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. 
  • Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. 
  • Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. 
  • Human apolipoprotein E accelerates microtubule polymerization in vitro. 
  • Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. 
  • Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. 
  • Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. 
  • Hypercholesterolemia induces oxidant stress that accelerates the ageing of hematopoietic stem cells. 
  • Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. 
  • Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. 
  • Imaging genetics of brain longevity and mental wellness: the next frontier? 
  • Imaging genomics. 
  • Impact of APOE genotype on prion-type propagation of tauopathy. 
  • Impact of APOE in mild cognitive impairment. 
  • Impact of psychological stress on the associations between apolipoprotein E variants and metabolic traits: findings in an American sample of caregivers and controls. 
  • Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. 
  • Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. 
  • Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. 
  • Independent associations of TOMM40 and APOE variants with body mass index. 
  • Influence of Western diet and APOE genotype on Alzheimer's disease risk. 
  • Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase. 
  • Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease. 
  • Inherited frailty. ApoE alleles determine survival after a diagnosis of heart disease or stroke at ages 85+. 
  • Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation. 
  • Inhibition of Blood-Brain Barrier Disruption by an Apolipoprotein E-Mimetic Peptide Ameliorates Early Brain Injury in Experimental Subarachnoid Hemorrhage. 
  • Inhibition of p38 Mitogen-Activated Protein Kinase Enhances the Apoptosis Induced by Oxidized Low-Density Lipoprotein in Endothelial Progenitor Cells. 
  • Initial observations of key features of age-related macular degeneration in APOE targeted replacement mice. 
  • Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis. 
  • Insulin increases central apolipoprotein E levels as revealed by an improved technique for collection of cerebrospinal fluid from rats. 
  • Inter- and intra-chromosomal modulators of the APOE ɛ2 and ɛ4 effects on the Alzheimer's disease risk. 
  • Interaction between the alpha-T catenin gene (VR22) and APOE in Alzheimer's disease. 
  • Interaction of apolipoprotein E with laminin increases neuronal adhesion and alters neurite morphology. 
  • Interaction of methylation-related genetic variants with circulating fatty acids on plasma lipids: a meta-analysis of 7 studies and methylation analysis of 3 studies in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium. 
  • Interactions between life stress factors and carrying the APOE4 allele adversely impact self-reported health in old adults. 
  • Intracerebral hemorrhage outcome: apolipoprotein E genotype, hematoma, and edema volumes. 
  • Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. 
  • Investigation of potential gene-gene interactions between APOE and RELN contributing to autism risk. 
  • Is the APOE epsilon4 genotype associated with higher hospital costs among elderly patients? 
  • Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. 
  • Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. 
  • Joint effects of smoking history and APOE genotypes in age-related macular degeneration. 
  • Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis. 
  • Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. 
  • Learning and recall in subjects at genetic risk for Alzheimer's disease. 
  • Longitudinal follow-up of late-onset Alzheimer disease families. 
  • Longitudinal modeling of cognitive aging and the TOMM40 effect. 
  • Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. 
  • Lowering circulating apolipoprotein E levels improves aged bone fracture healing. 
  • Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. 
  • Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an Alzheimer disease-related brain network. 
  • Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. 
  • Mediation of the APOE associations with Alzheimer's and coronary heart diseases through body mass index and lipids. 
  • Medicine. Old drug, new hope for Alzheimer's disease. 
  • Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. 
  • Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. 
  • Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. 
  • Microglial function in human APOE3 and APOE4 transgenic mice: altered arginine transport. 
  • Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. 
  • Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. 
  • Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. 
  • Mitochondrial DNA polymorphism A4917G is independently associated with age-related macular degeneration. 
  • Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. 
  • Molecular biology of apolipoprotein E. 
  • Molecular determinants and dynamics of hepatitis C virus secretion. 
  • Molecular genetics of AMD and current animal models. 
  • Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. 
  • Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice. 
  • Mortality and apolipoprotein E in African-American, and White elders: an attempted replication. 
  • Multicenter cohort study on association of genotypes with prospective sports concussion: methods, lessons learned, and recommendations. 
  • Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. 
  • NEBULA is a fast negative binomial mixed model for differential or co-expression analysis of large-scale multi-subject single-cell data. 
  • Near-infrared spectrometry of abdominal aortic aneurysm in the ApoE-/- mouse. 
  • Neighborhoods, sleep quality, and cognitive decline: Does where you live and how well you sleep matter? 
  • Neuropathologic features of TOMM40 '523 variant on late-life cognitive decline. 
  • Neuroprotective Pentapeptide, CN-105, Improves Outcomes in Translational Models of Intracerebral Hemorrhage. 
  • Neuroprotective pentapeptide CN-105 improves functional and histological outcomes in a murine model of intracerebral hemorrhage. 
  • Neuroprotective pentapeptide CN-105 is associated with reduced sterile inflammation and improved functional outcomes in a traumatic brain injury murine model. 
  • Neuropsychological performance in advanced age: influences of demographic factors and Apolipoprotein E: findings from the Cache County Memory Study. 
  • New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics. 
  • New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. 
  • No association between alpha 1-antichymotrypsin and familial Alzheimer's disease. 
  • No association between the APOE gene and autism. 
  • No association between the HLA-A2 allele and Alzheimer disease. 
  • No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease. 
  • No genetic effect of alpha1-antichymotrypsin in Alzheimer disease. 
  • Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid. 
  • Novel loci and pathways significantly associated with longevity. 
  • Nox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaques. 
  • Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. 
  • Oxidized low-density lipoprotein induces apoptosis in endothelial progenitor cells by inactivating the phosphoinositide 3-kinase/Akt pathway. 
  • Parental education and late-life dementia in the United States. 
  • Patterns of brain activation in people at risk for Alzheimer's disease. 
  • Peripheral sensory nerve defects in apolipoprotein E knockout mice. 
  • Periventricular leukomalacia is common after neonatal cardiac surgery. 
  • Persistent mild cognitive impairment in geriatric depression. 
  • Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. 
  • Plasma clearance and liver uptake of chylomicron remnants generated by hepatic lipase lipolysis: evidence for a lactoferrin-sensitive and apolipoprotein E-independent pathway. 
  • Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. 
  • Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. 
  • Potential implications of Apolipoprotein E in early brain injury after experimental subarachnoid hemorrhage: Involvement in the modulation of blood-brain barrier integrity. 
  • Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease. 
  • Predictors of cognitive decline after cardiac operation. 
  • Prefrontal activation patterns in subjects at risk for Alzheimer disease. 
  • Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. 
  • Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. 
  • Preliminary report on the interaction of apolipoprotein E polymorphism with aortic atherosclerosis and acute nephropathy after CABG. 
  • Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice. 
  • Probing the role of PPARγ in the regulation of late-onset Alzheimer's disease-associated genes. 
  • Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. 
  • Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. 
  • Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. 
  • Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. 
  • Protective effect of apolipoprotein E-mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cell cultures. 
  • Protein: protein interactions in Alzheimer's disease and the CAG triplet repeat diseases. 
  • Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimer's disease. 
  • Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. 
  • Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions. 
  • Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. 
  • Regional CBF in apolipoprotein E-deficient and wild type mice during focal cerebral ischemia. 
  • Regional-specific effects of ovarian hormone loss on synaptic plasticity in adult human APOE targeted replacement mice. 
  • Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. 
  • Religiosity and Telomere Length: Moderating Effect of Religiosity on the Relationship Between High-Risk Polymorphisms of the Apolipoprotein E and TOMM40 Gene and Telomere Length. 
  • Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. 
  • Role for Nox1 NADPH oxidase in atherosclerosis. 
  • Role of white matter lesions, cerebral atrophy, and APOE on cognition in older persons with and without dementia: the Cache County, Utah, study of memory and aging. 
  • SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. 
  • Sequestration of amyloid beta-peptide. 
  • Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome. 
  • Sex steroids, APOE genotype and the innate immune system. 
  • Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. 
  • Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders. 
  • Sex-specific genetic predictors of Alzheimer's disease biomarkers. 
  • Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. 
  • Single-cell RNA sequencing reveals time- and sex-specific responses of mouse spinal cord microglia to peripheral nerve injury and links ApoE to chronic pain. 
  • Smoking, Alzheimer's disease, and confounding with genes. 
  • Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. 
  • Statin use and need for therapy in chronic lymphocytic leukemia. 
  • Strategies for dissecting genetic-environmental interactions in neurodegenerative disorders. 
  • TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. 
  • TOMM40-APOE haplotypes are associated with cognitive decline in non-demented Blacks. 
  • Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. 
  • Taste, smell and neuropsychological performance of individuals at familial risk for Alzheimer's disease. 
  • The APOE ε4 allele is associated with a reduction in FEV1/FVC in women: A cross-sectional analysis of the Long Life Family Study. 
  • The APOE-E4 allele and the risk of functional decline in a community sample of African American and white older adults. 
  • The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice. 
  • The Effect of the Relationship of APOE Polymorphisms and Cerebral Vasospasm on Functional Outcomes in Children With Traumatic Brain Injury. 
  • The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction. 
  • The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes. 
  • The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage. 
  • The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. 
  • The apolipoprotein E genotype predicts longitudinal transitions to mild cognitive impairment but not to Alzheimer's dementia: findings from a nationally representative study. 
  • The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappaB activation. 
  • The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features. 
  • The arterial wall and the atherosclerotic lesion. 
  • The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer's disease. 
  • The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes. 
  • The distribution of cerebrovascular amyloid in Alzheimer's disease varies with ApoE genotype. 
  • The effects of PPARγ on the regulation of the TOMM40-APOE-C1 genes cluster. 
  • The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes. 
  • The genetics of dementia in late life. 
  • The impact of APOE genotype on survival: Results of 38,537 participants from six population-based cohorts (E2-CHARGE). 
  • The importance of being connected. 
  • The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. 
  • The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury. 
  • The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. 
  • The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. 
  • The role of apolipoprotein E in the nervous system. 
  • The role of epigenetics in the endothelial cell shear stress response and atherosclerosis 
  • The role of lipid-related genes, aging-related processes, and environment in healthspan. 
  • Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury. 
  • There is a pathologic relationship between ApoE-epsilon 4 and Alzheimer's disease. 
  • Tracking brain volume changes in C57BL/6J and ApoE-deficient mice in a model of neurodegeneration: a 5-week longitudinal micro-MRI study. 
  • Trade-off in the effect of the APOE gene on the ages at onset of cardiocascular disease and cancer across ages, gender, and human generations. 
  • Trade-off in the effects of the apolipoprotein E polymorphism on the ages at onset of CVD and cancer influences human lifespan. 
  • Traumatic brain injury exacerbates neurodegenerative pathology: improvement with an apolipoprotein E-based therapeutic. 
  • Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression. 
  • Treatment of type III hyperlipoproteinemia. 
  • Tumor necrosis factor receptor-2 signaling attenuates vein graft neointima formation by promoting endothelial recovery. 
  • Twin pairs discordant for neuropathologically confirmed Lewy body dementia. 
  • Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. 
  • Understanding Alzheimer's disease in the context of aging: Findings from applications of stochastic process models to the Health and Retirement Study. 
  • Understanding the genetics of APOE and TOMM40 and role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease. 
  • Vascular smooth muscle actin is reduced in Alzheimer disease brain: a quantitative analysis. 
  • Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. 
  • Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. 
  • Zebrafish as a model for apolipoprotein biology: comprehensive expression analysis and a role for ApoA-IV in regulating food intake. 
  • [Investigation of neuroprotective activity of apolipoprotein E peptide mimetic Cog1410 in transgenic lines of Drosophila melanogaster]. 
• 

  Keywords of People

  • Bowes Rickman, Catherine, George and Geneva Boguslavsky Distinguished Professor of Eye Research, Cell Biology
  • Charles, Hal Cecil, Adjunct Associate Professor in the Department of Radiology, Radiology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma